Nektar Therapeutics to Participate in Two Investor Conferences in November
PR Newswire•11/11/2026•16:15 ET
0
Key Highlights
- ➤Nektar management to attend UBS Global Biopharma Conference November 17
- ➤Nektar management to attend Jefferies Global Healthcare Conference November 18
- ➤Rezpegaldesleukin remains Nektar’s lead clinical-stage product candidate
- ➤Company pipeline includes preclinical TNFR2 antibody, bispecific, and CSF programs
Nektar Therapeutics to Participate in Two Investor Conferences in November PR Newswire
SAN FRANCISCO, Nov. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in two upcoming investor conferences.
Get started
Create a free account to read the full story.